<?xml version="1.0" encoding="UTF-8"?>
<p>The previous statement might seem contradictory when looking to a well-known reality: in several European countries, follow-on/ similar formulations were previously approved without consulting, and prior to, the introduction of current regulatory guidance documents. In such cases, there was no major discussion or previous establishment of any meaningful preclinical standard for relevant clinical comparability, and certainly no debate or scientific comparison looking into potential substitution or interchangeability (
 <xref rid="B17" ref-type="bibr">17</xref>, 
 <xref rid="B18" ref-type="bibr">18</xref>).
</p>
